Orlistat
Orlistat has been studied in 87 papers since 2009: 10 trials and 20 observational studies in people, 3 in animals, 54 reviews; 37 in the past year. It is an approved medicine. The newest paper, Nov 19, 2026: “Weight-gain-related reporting for anti-obesity medications compared to tirzepatide in United States Food and Drug Administration Adverse Event Reporting System (FAERS)”.
9 new papers in 30 daysSee all 89 papers on orlistat
At a glance
The findings reach people, from one lab or study. 7 independent labs in 5 countries; 31 trials, 1 about aging, 11 with no results posted.
“Estimates were 2.30 (1.57–3.39) for orlistat, 1.63 (1.31–2.04) for phentermine-topiramate, and 1.58 (1.30–1.93) for naltrexone–bupropion.”
None of its findings points the other way.
- 7 independent labs in 5 countries
- 31 trials, 1 about aging, 11 with no results posted
- Funders: Academy of Medical Sciences and 2 more
- 4 of 31 trials sponsored by its developers
- Human trial10
- Humans20
- Animals2
What did studies of orlistat find?
11Studies of orlistat measured 11 outcomes, among them body weight, Fat-soluble vitamin absorption and triglyceride.
Body weight
downin humans1downin reviews1
2 studies
Body weight
downin humans1downin reviews1
Orlistat is linked with lower body weight in humans (-1.2 kg (p=0.002)).
“At 12-16 weeks after starting orlistat and liraglutide, weight losses of -1.2kg (p=0.002) and -4.1kg (p<0.001) were observed, respectively”
Humans12-16 weeks
Expert opinion on pharmacotherapy
Orlistat decreases body weight.
“which is an inhibitor of pancreatic and hepatic lipases that induces weight loss”
Review
Lipid Hydrolase Enzymes: Pragmatic Prolongevity Targets for Improved Human Healthspan?
Rejuvenation research
Fat-soluble vitamin absorption
downin reviews1
1 study
Fat-soluble vitamin absorption
downin reviews1
Orlistat decreases fat-soluble vitamin absorption (due to inhibition of intestinal fat absorption).
“Orlistat has been consistently associated with reduced absorption of fat-soluble vitamins due to inhibition of intestinal fat absorption”
Reviewdue to inhibition of intestinal fat absorption
Nutritional deficiencies associated with anti-obesity pharmacotherapy
International Journal of Community Medicine and Public Health
Triglyceride
no changein humans1
1 study
Triglyceride
no changein humans1
Orlistat showed no clear effect on triglyceride in humans (primary analysis in adults with dyslipidemia) (SMD -0.1668, 95% CI -0.7979 to 0.4642).
“TG: SMD [95% CI] -0.1668 [-0.7979; 0.4642], I 2 = 97.7% p value (heterogeneity) < 0.0001”
Reviewprimary analysis in adults with dyslipidemian = 1,369
Journal of obesity
Waist circumference
no changein humans1
1 study
Waist circumference
no changein humans1
Orlistat showed no clear effect on waist circumference in humans (primary analysis in adults with dyslipidemia) (SMD -0.1562, 95% CI -0.3138 to 0.0015).
“Changes in waist circumference (WC) and triglycerides (TGs) did not reach statistical significance in the primary analysis”
Reviewprimary analysis in adults with dyslipidemian = 1,369
Journal of obesity
HDL-C
downin humans1
1 study
HDL-C
downin humans1
Orlistat decreases HDL-C in adults with dyslipidemia (SMD -0.31, 95% CI -0.48 to -0.13).
“it was associated with a decrease in high-density lipoprotein cholesterol (SMD (95% CI): -0.31 [-0.48, -0.13]”
Reviewin adults with dyslipidemian = 1,369
Journal of obesity
Body mass index
downin humans1
1 study
Body mass index
downin humans1
Orlistat decreases body mass index in adults with dyslipidemia (SMD -0.30, 95% CI -0.58 to -0.03).
“Orlistat reduced body mass index (BMI) (SMD [95% CI]: -0.30 [-0.58, -0.03], p value (heterogeneity) = 0.026)”
Reviewin adults with dyslipidemian = 1,369
Journal of obesity
Blood pressure
no changein humans1
1 study
Blood pressure
no changein humans1
Orlistat showed no clear effect on blood pressure in humans (metabolic dysfunction-associated steatotic liver disease).
“Orlistat did not significantly affect BP.”
Reviewmetabolic dysfunction-associated steatotic liver disease
Current therapeutic research, clinical and experimental
Body mass index
downin humans1
1 study
Body mass index
downin humans1
Orlistat decreases body mass index in humans (metabolic dysfunction-associated steatotic liver disease) (WMD -0.99 kg/m2, 95% CI -1.18 to -0.81).
“BMI decreased significantly overall (WMD: -0.99 kg/m2, 95% CI: -1.18 to -0.81, P < 0.001), with stronger effects in long-term interventions.”
Reviewmetabolic dysfunction-associated steatotic liver disease
Current therapeutic research, clinical and experimental
Alanine aminotransferase
downin humans1
1 study
Alanine aminotransferase
downin humans1
Orlistat decreases alanine aminotransferase in humans (metabolic dysfunction-associated steatotic liver disease) (WMD -8.70 U/L, 95% CI -16.51 to -0.90).
“ALT (WMD: -8.70 U/L, 95% CI: -16.51 to -0.90, P = 0.036)”
Reviewmetabolic dysfunction-associated steatotic liver disease
Current therapeutic research, clinical and experimental
Gastrointestinal discomfort
upin humans1
1 study
Gastrointestinal discomfort
upin humans1
Orlistat increases gastrointestinal discomfort in humans.
“side effects such as gastrointestinal discomfort with orlistat and GLP-1 receptor agonists”
Review
Cureus
All 11Fewer
What is orlistat linked with?
2Studies link orlistat with 2 measures: Weight-gain-related reporting and steatorrhea.
Weight-gain-related reporting
upin humans1
1 study
Weight-gain-related reporting
upin humans1
Orlistat is associated with weight-gain-related reporting in humans (Compared with tirzepatide; five-term reporting definition) (Adjusted reporting odds ratio 2.30 (95% CI 1.57–3.39)).
“Estimates were 2.30 (1.57–3.39) for orlistat, 1.63 (1.31–2.04) for phentermine-topiramate, and 1.58 (1.30–1.93) for naltrexone–bupropion.”
HumansCompared with tirzepatide; five-term reporting definition2023–2025
Frontiers in pharmacology
Steatorrhea
upin humans1
1 study
Steatorrhea
upin humans1
Orlistat is associated with steatorrhea in humans.
“Orlistat commonly linked to steatorrhea and flatulence”
Review
Medicina (Kaunas, Lithuania)
Has orlistat been tested in people?
1 of 31 about agingYes: 10 trials and 20 observational studies in people have been published, and 30 trials are registered.
About aging
Approved
Jul 29, 1998Obesity, Overweight
Apr 23, 1999Obesity, Overweight, excess body weight
Feb 7, 2007Overweight
EMA Alli (previously Orlistat GSK)
Jul 22, 2007Obesity, Overweight
Repurposing
Phase 4Terminated3 trials
Phase 4Completed2 trials
Metabolic dysfunction-associated steatotic liver disease
Phase 4Completed2 trials
Phase 4Completed1 trial
Phase 3Completed1 trial
Phase 4Status unknown2 trials
All 18Fewer
Every condition in trials
Hyperlipoproteinemia Type I
Phase 2Results posted1 trial
Stopped
NCT00115063TerminatedObesity
ethical issues of continuing control group without treatment
NCT04531176TerminatedObesity
After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.
NCT01351753TerminatedDyslipidemias
Lack of funding
NCT01675154TerminatedHypertriglyceridemia
Due to unavailability of the drug.
Trial sponsors
Company2 trialsPhase 4110 people
Company1 trialPhase 3638 people
Company1 trialPhase 2600 people
Company1 trialPhase 2486 people
Affiliated Hospital of Nantong University
2 trialsPhase 4244 people
Pennington Biomedical Research Center
1 trialPhase 4390 people
National Institute of Diabetes and Digestive and Kidney Diseases
1 trialPhase 4246 people
Aristotle University Of Thessaloniki
1 trialPhase 4200 people